Related Experiment Video
Updated: Jul 15, 2026
Transplantation of Cells Directly into the Kidney of Adult Zebrafish
Published on: May 18, 2011
Fish oil for kidney transplant recipients
A K H Lim1, K J Manley, M A Roberts
1Monash Medical Centre, Department of Nephrology, 246 Clayton Rd, Clayton, Victoria, Australia, 3168. Andy.lim@med.monash.edu.au
Background:
Calcineurin inhibitors used in kidney transplantation for immunosuppression have adverse effects that may contribute to nephrotoxicity and increased cardiovascular risk profile. Fish oils are rich in very long chain omega-3 fatty acids, which may reduce nephrotoxicity by improving endothelial function and reduce rejection rates through their immuno-modulatory effects. They may also modify the cardiovascular risk profile. Hence, fish oils may potentially prolong graft survival and reduce cardiovascular mortality.
Objectives:
To assess the benefits and harms of fish oil supplementation on kidney transplant recipients on a calcineurin inhibitor-based immunosuppressive regimen.
Search Strategy:
We searched the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library, issue 2 2005), MEDLINE (1966-April 2005) and EMBASE (1980-April 2005).
Selection Criteria:
All randomised controlled trials (RCTs) and quasi-RCTs of fish oils in kidney transplant recipients on a calcineurin inhibitor-based immunosuppressive regimen. RCTs of fish oil versus statins were included.
Data Collection And Analysis:
Data was extracted and the quality of studies assessed by two authors, with differences resolved by discussion with a third independent author. Dichotomous outcomes were reported as relative risk (RR) and continuous outcome measures were reported as the mean difference (MD) with 95% confidence intervals using the random effects model. Heterogeneity was assessed using a Chi(2) test on n-1 degrees of freedom and the I(2) statistic. Data not suitable for pooling were tabulated and described.
Main Results:
Sixteen studies (733 patients) were suitable for analysis. Fish oil did not significantly affect patient or graft survival, acute rejection rates, calcineurin inhibitor toxicity or renal function, when compared to placebo. Fish oil treatment was associated with a lower diastolic blood pressure (MD 4.5 mmHg; P = 0.004) compared to placebo. Patients receiving fish oil for more than six months had a modest increase in HDL (MD 0.12 mmol/L; P = 0.01) compared to placebo. Fish oil effects on lipids were not significantly different from low-dose statins. There was insufficient data to analyse cardiovascular outcomes. Fishy aftertaste and gastrointestinal upset were common but did not result in significant patient drop-out.
Authors' Conclusions:
There is insufficient evidence from currently available RCTs to recommend fish oil therapy to improve renal function, rejection rates, patient survival or graft survival. The improvements in HDL cholesterol and diastolic blood pressure were too modest to recommend routine use. To determine a benefit in clinical outcomes, future RCTs will need to be adequately powered with these outcomes in mind.
Insights
Fish oil supplementation did not significantly improve outcomes for kidney transplant patients on calcineurin inhibitors. Modest improvements in blood pressure and HDL cholesterol were observed, but evidence is insufficient for routine recommendation.
Area of Science:
- Nephrology
- Immunology
- Cardiology
Background:
- Calcineurin inhibitors (CNIs) in kidney transplantation can cause nephrotoxicity and increase cardiovascular risk.
- Fish oils, rich in omega-3 fatty acids, may mitigate these risks through improved endothelial function and immunomodulation.
- Potential benefits include reduced rejection rates, prolonged graft survival, and improved cardiovascular health.
Purpose of the Study:
- To evaluate the efficacy and safety of fish oil supplementation in kidney transplant recipients using CNI-based immunosuppression.
- To assess the impact on graft survival, rejection rates, renal function, and cardiovascular risk factors.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) and quasi-RCTs.
- Searched Cochrane CENTRAL, MEDLINE, and EMBASE databases.
- Extracted data, assessed study quality, and performed meta-analysis using random effects models.
Main Results:
- Sixteen studies (733 patients) were analyzed.
- Fish oil did not significantly impact patient/graft survival, acute rejection, CNI toxicity, or renal function compared to placebo.
- Associated with lower diastolic blood pressure and a modest increase in HDL cholesterol with longer-term use.
- No significant difference in lipid effects compared to low-dose statins.
Conclusions:
- Insufficient evidence from current RCTs supports fish oil therapy for improving renal function, rejection rates, or survival in kidney transplant patients.
- Observed improvements in HDL cholesterol and diastolic blood pressure are too modest for routine recommendation.
- Future adequately powered RCTs are needed to determine clinical benefits.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention